Clinical Trial Update: A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating galunisertib in combination with nivolumab for advanced solid tumors, including recurrent or refractory non-small cell lung cancer an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• Galunisertib (galunisertib)
• nivolumab (nivolumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor, Non-Small Cell Lung Cancer Recurrent | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-09